224 related articles for article (PubMed ID: 38194088)
21. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
[TBL] [Abstract][Full Text] [Related]
22. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
24. [Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].
Nguyen K; Korsing S; Mansour Y; Meier K
Dermatologie (Heidelb); 2023 Oct; 74(10):787-792. PubMed ID: 37407876
[TBL] [Abstract][Full Text] [Related]
25. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
26. A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients.
Gong C; Liu Y; Zhang M
Ther Adv Hematol; 2024; 15():20406207241251602. PubMed ID: 38832237
[TBL] [Abstract][Full Text] [Related]
27. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
28. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review.
Rauh MJ; Rahman F; Good D; Silverman J; Brennan MK; Dimov N; Liesveld J; Ryan DH; Burack WR; Bennett JM
Leuk Res; 2012 Jan; 36(1):81-6. PubMed ID: 21890199
[TBL] [Abstract][Full Text] [Related]
29. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.
Pagano L; Valentini CG; Grammatico S; Pulsoni A
Br J Haematol; 2016 Jul; 174(2):188-202. PubMed ID: 27264021
[TBL] [Abstract][Full Text] [Related]
30. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
31. Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.
Johnson RC; Kim J; Natkunam Y; Sundram U; Freud AG; Gammon B; Cascio MJ
Am J Surg Pathol; 2016 Apr; 40(4):502-9. PubMed ID: 26796502
[TBL] [Abstract][Full Text] [Related]
32. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
Wu SJ; Sadigh S; Lane AA; Pinkus GS
Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
[TBL] [Abstract][Full Text] [Related]
33. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
[TBL] [Abstract][Full Text] [Related]
34. [Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
Ahogo KC; Wantz M; Cliquennois M; Gosset P; Lebas D; Modiano P
Ann Dermatol Venereol; 2014 Jan; 141(1):43-7. PubMed ID: 24461094
[TBL] [Abstract][Full Text] [Related]
35. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
Paluri R; Nabell L; Borak S; Peker D
Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
[TBL] [Abstract][Full Text] [Related]
36. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
37. Blastic plasmacytoid dendritic cell neoplasm: A clinicopathological diagnostic dilemma report of three cases with review of literature.
Purkait S; Gupta S; Bakhshi S; Mallick S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S471-S474. PubMed ID: 36511007
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm.
Cronin DM; George TI; Reichard KK; Sundram UN
Am J Clin Pathol; 2012 Mar; 137(3):367-76. PubMed ID: 22338048
[TBL] [Abstract][Full Text] [Related]
39. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
Jen WY; Konopleva M; Pemmaraju N
Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
[TBL] [Abstract][Full Text] [Related]
40. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
